Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
2
50%
Ph early_phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Completed1
Terminated1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

completed125%
terminated125%
recruiting125%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
recruiting

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

NCT03958565
completedphase_2

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

NCT03792763
unknownearly_phase_1

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

NCT03691311
terminatedphase_2

Reduced Dose-density of Denosumab for Unresectable GCTB

NCT03620149

Clinical Trials (4)

Showing 4 of 4 trials
NCT03958565

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting
NCT03792763Phase 2

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients

Completed
NCT03691311Early Phase 1

Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer

Unknown
NCT03620149Phase 2

Reduced Dose-density of Denosumab for Unresectable GCTB

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4